Cowen & Co. Thinks Aptinyx Inc’s Stock is Going to Recover

By Austin Angelo

In a report released today, Ritu Baral from Cowen & Co. maintained a Buy rating on Aptinyx Inc (APTXResearch Report). The company’s shares opened today at $3.47, close to its 52-week low of $2.88.

According to TipRanks.com, Baral is a top 100 analyst with an average return of 25.1% and a 48.1% success rate. Baral covers the Healthcare sector, focusing on stocks such as Milestone Pharmaceuticals Inc, Madrigal Pharmaceuticals Inc, and ACADIA Pharmaceuticals Inc.

The word on The Street in general, suggests a Strong Buy analyst consensus rating for Aptinyx Inc with a $13.50 average price target.

See today’s analyst top recommended stocks >>

Based on Aptinyx Inc’s latest earnings release for the quarter ending March 31, the company reported a quarterly GAAP net loss of $16.71 million. In comparison, last year the company had a GAAP net loss of $11.67 million.

Based on the recent corporate insider activity of 36 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of APTX in relation to earlier this year.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Aptinyx Inc. is a clinical stage biopharmaceutical company. It engages in the discovery, development, and and commercialization of transformative therapies for disorders of the brain and nervous system. Its product includes NYX-2925, NYX-783, NYX-458, and the AGN-241751 program.